Fever of Unknown Origin (FUO)¶

Chapter 22 | Part 2: Cardinal Manifestations and Presentation of Diseases

KEY CLINICAL POINTS¶

FUO is defined as fever ≥ 38.3°C ( ≥ 101°F) on at least two occasions, illness duration ≥ 3 weeks, no known immunocompromised state, and uncertain diagnosis despite obligatory investigations
Infections remain the most common cause worldwide, but noninfectious inflammatory diseases (NIIDs) predominate in Western cohorts; up to 50% of Western FUO cases remain undiagnosed
Potentially diagnostic clues (PDCs) from repeated history, physical examination, and obligatory tests guide the diagnostic approach
18F-FDG-PET/CT has emerged as a key diagnostic tool with ~50% diagnostic yield, best performed during active inflammation with elevated inflammatory markers
Most patients with unexplained FUO have favorable outcomes; empirical therapeutic trials should be avoided except in rapidly deteriorating patients

1. DEFINITION & OVERVIEW¶

Fever of unknown origin (FUO) refers to prolonged febrile illnesses without an established etiology despite intensive evaluation and diagnostic testing. The term should be reserved for cases meeting specific criteria, distinguishing them from common febrile illnesses that either resolve spontaneously or develop distinguishing characteristics leading to diagnosis.

1.1 Current Diagnostic Criteria¶

FUO is defined by four criteria: 1. Fever ≥ 38.3°C ( ≥ 101°F) on at least two occasions 2. Illness duration of at least 3 weeks 3. No known immunocompromised state 4. Diagnosis remains uncertain after thorough history-taking, physical examination, and obligatory investigations

1.2 Obligatory Investigations Required for FUO Diagnosis¶

The following tests must be performed before classifying a case as FUO: - Inflammatory markers: ESR and CRP level - Hematology: Platelet count, leukocyte count and differential, hemoglobin - Chemistry: Electrolytes, creatinine, total protein, alkaline phosphatase, ALT, AST, LDH, creatine kinase, ferritin - Immunology: Antinuclear antibodies (ANA), rheumatoid factor, protein electrophoresis - Microbiology: Blood cultures (n = 3), urine culture - Imaging: Chest x-ray, abdominal ultrasonography - Tuberculosis screening: Tuberculin skin test (TST) or interferon γ release assay (IGRA) - Urinalysis

1.3 Inflammation of Unknown Origin (IUO)¶

IUO shares the same definition as FUO except for the body temperature criterion. IUO is defined as elevated inflammatory parameters (CRP or ESR) on multiple occasions for at least 3 weeks in an immunocompetent patient with normal body temperature, without final explanation despite standard workup. Studies demonstrate that causes and workup for IUO and FUO are identical.

1.4 Historical Evolution of Definition¶

Originally defined by Petersdorf and Beeson in 1961 as illness of ≥ 3 weeks' duration with fever ≥ 38.3°C on two occasions and uncertain diagnosis despite 1 week of inpatient evaluation. Modern modifications reflect outpatient-based healthcare and exclude immunocompromised patients who require different, more aggressive approaches. Qualitative criteria of minimal diagnostic testing are now necessary to reduce heterogeneity between cohorts.

2. EPIDEMIOLOGY¶

The prevalence of FUO varies significantly between geographic regions and healthcare settings. Limited data exist, but Japanese studies from the 1990s reported a prevalence of 2.9% among admitted patients. A recent Danish registry study identified 6220 patients over a 10-year period.

Etiology of FUO: Pooled Results of Large Studies (2003-2023)¶

Geographi c Area	No. of Cohorts (Inclusion Period)	No. of Patients	Infections, Median % (Range)	NIIDs, Median % (Range)	Malignanc y, Median % (Range)	Miscellane ous, Median % (Range)	No Diagnosis, Median % (Range)
Western Europe	12 (1995-2 020)	2100	15.5 (4-36)	25 (17-33)	11 (3-30)	7.5 (0-16)	39.5 (26-54)
Other European and Turkey	15 (1984-2 019)	1615	42 (26-74)	23 (12-38)	14 (4-19)	5 (2-18)	16 (0-35)
Middle East	3 (2009-20 10)	1289	66 (42-79)	15 (7-17)	7 (1-30)	1 (0-12)	8 (2-12)
Asia	39 (1994-2 021)	7191	42 (3-58)	19 (7-57)	13 (6-23)	6.5 (0-15)	17 (0-81)

2.1 Geographic Variation in Etiology¶

The distribution of FUO causes varies markedly by region: - Western Europe: NIIDs are the most common cause; infections account for only 15.5% (median); up to 39.5% remain undiagnosed - Middle East: Infections predominate (66% median), with only 8% remaining undiagnosed - Asia: Infections account for 42% (median); NIIDs for 19% - Other European countries and Turkey: Infections 42%, NIIDs 23% No large studies have been reported from the Americas, Africa, or Oceania.

2.2 Risk Factors for Specific Diagnoses¶

Infection risk: 4× higher in Southern Asia, 3× higher in Far East Asia compared to Europe
Tuberculosis: Accounts for up to 50% of all infections in FUO patients outside Western nations
Giant cell arteritis: Prevalence up to 17% among elderly FUO patients
Recurrent inflammation: Associated with lower (but not zero) prevalence of infections
Symptom duration >12 months: Lower chance of final diagnosis; infections and malignancy less common but still possible

2.3 The FUO Paradox¶

In Western cohorts, the proportion of undiagnosed patients can exceed 50%, paradoxically higher than 60 years ago despite technical advances. This is explained by: 1. Earlier diagnosis of many conditions due to readily available CT, MRI, and PET/CT 2. Patients seeking medical advice earlier 3. Only the most difficult-to-diagnose cases now meeting FUO criteria 4. Most undiagnosed FUO patients doing well clinically, allowing less aggressive diagnostic approaches

2.4 Prognostic Indicators¶

No reliable clinical parameters identify patients at high risk of remaining undiagnosed
Symptom duration >12 months: Significantly associated with lower diagnostic yield
Normal PET/CT: Associated with lower chance of final diagnosis
Recurrent inflammation pattern: Reduces chance of finding final explanation
Study origin: Chance of remaining undiagnosed is 2-5× higher in European vs Asian patients

3. ETIOLOGY & PATHOPHYSIOLOGY¶

Patients with FUO most often have an atypical presentation of a common disease rather than a rare disease. The range of FUO etiologies has evolved since the 1960s due to changes in definition, local disease epidemiology, widespread antibiotic use, and availability of new diagnostic techniques.

Reported Causes of FUO - Infections¶

Category	Specific Causes
Bacterial, nonspecific	Abdominal abscess, aortitis, appendicitis, bronchiectasis, cholangitis, cholecystitis, diverticulitis, endocarditis, epidural abscess, infected joint/vascular prosthesis, liver/lung abscess, mastoiditis, osteomyelitis, pelvic inflammatory disease, prostatitis, pyelonephritis, septic arthritis, sinusitis, spondylodiscitis
Bacterial, specific	Actinomycosis, bartonellosis, brucellosis, Chlamydia pneumoniae, legionellosis, leptospirosis, listeriosis, Lyme disease, melioidosis, nocardiosis, nontuberculous mycobacteria, psittacosis, Q fever, rickettsiosis, syphilis, tuberculosis, tularemia, typhoid fever, Whipple disease, yersiniosis
Fungal	Aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, cryptococcosis, histoplasmosis, mucormycosis, Pneumocystis jirovecii, sporotrichosis
Parasitic	Amebiasis, babesiosis, echinococcosis, malaria, schistosomiasis, toxoplasmosis, trichinellosis, trypanosomiasis, visceral leishmaniasis
Viral	CMV, chikungunya, dengue, EBV, hantavirus, hepatitis (A-E), HIV, HSV, HHV-6, parvovirus, West Nile virus

Reported Causes of FUO - Noninfectious Inflammatory Diseases¶

Category	Specific Causes
Systemic rheumatic/autoimmune	Ankylosing spondylitis, antiphospholipid syndrome, autoimmune hepatitis, Behçet's disease, dermatomyositis, Felty syndrome, gout, mixed connective tissue disease, polymyositis, pseudogout, reactive arthritis, relapsing polychondritis, rheumatoid arthritis, Sjögren's syndrome, SLE, systemic sclerosis
Vasculitis	ANCA vasculitis, Cogan's syndrome, eosinophilic granulomatosis with polyangiitis, giant cell vasculitis/polymyalgia rheumatica, granulomatosis with polyangiitis, IgA vasculitis, Kawasaki disease, polyarteritis nodosa, Takayasu arteritis, urticarial vasculitis
Granulomatous diseases	Idiopathic granulomatous hepatitis, sarcoidosis
Autoinflammatory syndromes	Blau syndrome, CAPS (CINCA/NOMID, FCAS, Muckle-Wells), Crohn's disease, DADA2, DIRA, familial Mediterranean fever, hyper-IgD syndrome (HIDS), juvenile idiopathic arthritis, macrophage activation syndrome, PAPA, PFAPA, recurrent idiopathic pericarditis, SAPHO, Schnitzler's syndrome, Still's disease, TRAPS, VEXAS

Reported Causes of FUO - Neoplasms and Miscellaneous¶

Category	Specific Causes
Hematologic malignancies	Amyloidosis, angioimmunoblastic lymphoma, Castleman's disease, hemophagocytic syndrome (HLH), Hodgkin's disease, hypereosinophilic syndrome, leukemia, lymphomatoid granulomatosis, multiple myeloma, myelodysplastic syndrome, myelofibrosis, non-Hodgkin's lymphoma, systemic mastocytosis
Solid tumors	Breast, colon, hepatocellular, lung, pancreatic, and renal cell carcinomas (most common causing FUO); most solid tumors and metastases can cause fever
Miscellaneous	Adrenal insufficiency, aortic dissection, atrial myxoma, cholesterol emboli, cirrhosis, drug fever, Erdheim-Chester disease, factitious fever, fraudulent fever, Gaucher's disease, hematoma, IgG4 disease, Kikuchi's disease, panniculitis, POEMS, pulmonary embolism, retroperitoneal fibrosis, Rosai-Dorfman disease, subacute thyroiditis, Sweet's syndrome, TAFRO syndrome
Thermoregulatory - Central	Brain tumor, cerebrovascular accident, encephalitis, hypothalamic dysfunction
Thermoregulatory - Peripheral	Anhidrotic ectodermal dysplasia, benign hyperthermia, exercise-induced hyperthermia, heat stroke, hyperthyroidism, pheochromocytoma

3.1 Temporal Changes in Etiology¶

Conditions now LESS common as FUO causes: - Intraabdominal abscesses (earlier detection by CT/ultrasound) - Tumors (improved imaging) - Infective endocarditis (improved blood culture and echocardiography) Conditions now recognized as FUO causes: - Acute HIV infection - Autoinflammatory diseases (including newly described syndromes) - VEXAS syndrome (described in >300 patients since 2020)

3.2 Infectious Causes¶

Common infectious diagnoses in FUO: - Endocarditis (including culture-negative) - Diverticulitis - Vertebral osteomyelitis/spondylodiscitis - Extrapulmonary tuberculosis - Q fever (Coxiella burnetii) - Whipple's disease (Tropheryma whipplei) Culture-negative endocarditis organisms: - Nutritionally variant bacteria - HACEK organisms (Haemophilus parainfluenzae, H. paraphrophilus, Aggregatibacter actinomycetemcomitans, A. aphrophilus, A. paraphrophilus, Cardiobacterium hominis, C. valvarum, Eikenella corrodens, Kingella kingae) - Coxiella burnetii - Tropheryma whipplei - Bartonella species

3.3 Noninfectious Inflammatory Diseases (NIIDs)¶

NIIDs include autoimmune, autoinflammatory, granulomatous diseases, and vasculitides. Up to one-third of Western FUO patients have an NIID diagnosis. Common NIID diagnoses: - Adult-onset Still's disease - Large-vessel vasculitis/giant cell arteritis - Polymyalgia rheumatica - Systemic lupus erythematosus (SLE) - Sarcoidosis - Familial Mediterranean fever (specific geographic regions) - Schnitzler's syndrome (urticaria, bone pain, monoclonal gammopathy) NIIDs may precede typical manifestations by months; their proportion is unlikely to decrease as more genetic inflammatory syndromes are described.

3.4 VEXAS Syndrome¶

Vacuoles, E1 enzyme, X-linked autoinflammatory syndrome (VEXAS) is a newly described adult-onset multisystem autoinflammatory syndrome: - Demographics: Predominantly middle-aged to elderly males - Features: Recurrent inflammation, skin lesions, chondritis, lung disease, venous thrombosis, arthritis, myelodysplastic syndrome - Diagnostic clue: Vacuoles in myeloid precursors on bone marrow biopsy - Etiology: Somatic mosaicism for pathogenic variants in UBA1 gene

3.5 Malignancies¶

Most malignancies can present with fever, but malignant lymphoma is by far the most common FUO-associated neoplasm. Fever may precede detectable lymphadenopathy. Sterile (marantic) endocarditis: - Occurs as paraneoplastic phenomenon, especially with adenocarcinomas - Also seen in SLE and antiphospholipid syndrome

3.6 Miscellaneous Causes¶

Drug-induced fever: - Any drug can cause fever, even after long-term use - Common culprits: Allopurinol, carbamazepine, lamotrigine, phenytoin, sulfasalazine, furosemide, sulfonamides, minocycline, vancomycin, β -lactam antibiotics, isoniazid - DRESS/DIHS: Drug reaction with eosinophilia and systemic symptoms; often accompanied by eosinophilia and lymphadenopathy Benign/exercise-induced hyperthermia: - Elevated body temperature WITHOUT increased CRP, ESR, or other inflammation signs - May be postinfectious (triggers similar to chronic fatigue syndrome: EBV, Q-fever, COVID-19) Factitious fever: Patient artificially induces fever (e.g., IV injection of contaminated water) Fraudulent fever: Patient manipulates thermometer while normothermic; identified by simultaneous measurements at different body sites; pulse-temperature dissociation is a diagnostic clue

4. CLINICAL FEATURES¶

The clinical presentation of FUO depends entirely on the underlying cause. Key aspects include fever pattern, associated symptoms, and physical examination findings that may serve as potentially diagnostic clues (PDCs).

4.1 Fever Patterns¶

Important patterns to characterize: - Continuous vs. recurrent fever - Duration of episodes - Fever-free intervals (recurrent inflammation defined as episodes interspersed with fever-free intervals ≥ 2 weeks with apparent remission)

4.2 Potentially Diagnostic Clues (PDCs)¶

PDCs are defined as all localizing signs, symptoms, and abnormalities potentially pointing toward a diagnosis. They are the most critical element guiding further workup. Sources of PDCs: - History: Medical history, drug use, family history, sexual history, country of origin, travel history, environmental exposures, animal contacts - Physical examination: Eyes (fundoscopy for retinal vasculitis), lymph nodes, temporal arteries, liver, spleen, previous surgical sites, entire skin surface, mucous membranes - Obligatory investigations: Laboratory and imaging abnormalities Although PDCs are often misleading, they are essential for creating a focused differential diagnosis.

4.3 Special Clinical Presentations¶

Culture-negative endocarditis: - Fever with signs of endocarditis but negative blood cultures - Consider difficult-to-culture bacteria, HACEK organisms, Coxiella, Tropheryma, Bartonella Schnitzler's syndrome presentation: - Urticaria - Bone pain - Monoclonal gammopathy VEXAS presentation: - Recurrent inflammation - Skin lesions - Chondritis - Lung disease - Venous thrombosis - Arthritis - Features of myelodysplastic syndrome

4.4 Travel and Exposure History¶

Key associations: - Tropical countries/American Southwest: Consider malaria, leishmaniasis, histoplasmosis, coccidioidomycosis - Rural areas or animal product exposure: Consider Q fever (test by IFA) - CNS, GI, or joint symptoms: Consider Whipple's disease (PCR for T. whipplei on stool and blood)

5. DIFFERENTIAL DIAGNOSIS¶

The differential diagnosis for FUO is extensive and influenced by local epidemiology. The key principle is that FUO most often represents an atypical presentation of a common disease rather than a rare disease.

5.1 Major Diagnostic Categories¶

Infections (most common globally; ~15% in Western Europe, up to 66% in Middle East)
Noninfectious inflammatory diseases (most common in Western Europe at ~25%)
Malignancies (~7-14% depending on region)
Miscellaneous causes (~1-7.5%)
No diagnosis (8-40% depending on region and criteria used)

5.2 Common Specific Diagnoses by Category¶

Infections: - Endocarditis (including culture-negative) - Diverticulitis - Vertebral osteomyelitis/spondylodiscitis - Extrapulmonary/miliary tuberculosis - Q fever, Whipple's disease NIIDs: - Adult-onset Still's disease - Large-vessel vasculitis/giant cell arteritis - Polymyalgia rheumatica - SLE - Sarcoidosis - Schnitzler's syndrome Malignancies: - Malignant lymphoma (by far most common) - Solid tumors (especially breast, colon, hepatocellular, lung, pancreatic, renal cell) Miscellaneous: - Drug-induced fever - Benign/exercise-induced hyperthermia - Factitious/fraudulent fever

5.3 Conditions Requiring Special Consideration¶

Q fever: Test in patients with rural exposure, animal contact, heart valve disease, aortic aneurysm, or vascular prosthesis Whipple's disease: Test with PCR for T. whipplei in patients with unexplained CNS, GI, or joint symptoms Miliary tuberculosis: Difficult to diagnose; granulomatous disease on liver or bone marrow biopsy should prompt consideration; TST/IGRA may be falsely negative Giant cell arteritis: Consider in all patients ≥ 55 years; temporal artery biopsy recommended in this age group

6. INVESTIGATIONS & DIAGNOSIS¶

A structured diagnostic approach centered on identifying and pursuing potentially diagnostic clues (PDCs) is essential. The diagnostic algorithm proceeds from obligatory investigations through targeted testing to advanced imaging.

6.1 Structured Diagnostic Algorithm¶

Step 1: Confirm FUO criteria (fever ≥ 38.3°C, ≥ 3 weeks, immunocompetent, diagnosis uncertain after obligatory tests) Step 2: Pre-workup preparation - Stop antibiotic treatment and corticosteroids (both mask diagnoses) - Exclude thermometer manipulation (simultaneous measurements at rectum, ear, mouth) - Exclude drug fever (stop or replace all medications; if fever persists >72h after discontinuation, drug unlikely to be cause) Step 3: Complete obligatory investigations Step 4: Search for PDCs through: - Complete and repeated history-taking - Complete and repeated physical examination - Review of all obligatory test results Step 5: If PDCs present → Guided diagnostic tests Step 6: If PDCs absent or misleading → Cryoglobulin testing, fundoscopy, then 18F-FDG-PET/CT Step 7: If abnormal PET/CT → Confirmation of abnormality (biopsy, culture) Step 8: If normal PET/CT → Repeat history/physical, PDC-driven invasive testing Step 9: If stable condition without diagnosis → Follow-up for new PDCs, consider NSAIDs Step 10: If deterioration without diagnosis → Further diagnostic tests, consider therapeutic trial Step 11: Consider second opinion at FUO expert center

6.2 History and Physical Examination Priorities¶

History elements: - Fever pattern (continuous vs. recurrent) and duration - Previous medical history - Present and recent drug use (including nonprescription drugs and supplements) - Family history - Sexual history - Country of origin - Recent and remote travel - Environmental exposures (travel, hobbies) - Animal contacts Physical examination focus: - Eyes (fundoscopy by ophthalmologist early if no PDCs) - Lymph nodes - Temporal arteries (palpation) - Liver and spleen - Sites of previous surgery - Entire skin surface - Mucous membranes

6.3 Laboratory Investigations¶

Obligatory tests (see Definition section) Additional considerations: - Cryoglobulins: Valuable screening test given low cost and nonspecific presentations - Immunologic serologies beyond obligatory tests: Low yield without specific PDCs; more likely to yield false-positive results Blood cultures: - Perform 3 cultures initially - Culture long enough for fastidious organisms (HACEK group) - Inform laboratory of intent to test for unusual organisms - Use specialized media when history suggests Histoplasma, Legionella, etc. - Repeating >3 blood cultures is useless without new PDCs - Repeat cultures useful only if previous samples collected during or within 1 week of antibiotic treatment

6.4 18F-FDG-PET/CT¶

Mechanism: FDG accumulates in tissues with high glycolysis (malignant cells, activated leukocytes) Advantages over conventional scintigraphy: - Higher resolution - Greater sensitivity for chronic low-grade infections - High accuracy in central skeleton - Detects vascular uptake in vasculitis Diagnostic yield: ~50% (proportion of scans helpful in finding final explanation) Optimal timing: - Perform during active inflammation - Best with elevated CRP or ESR at time of scan - If both CRP and ESR normal, scan may only be contributory if patient has fever at time of scan Limitations: - Cannot differentiate infection vs. sterile inflammation vs. malignancy (but all can cause FUO) - Physiologic uptake may obscure pathologic foci in: brain, heart, bowel, kidneys, bladder - Heart uptake (obscures endocarditis): Prevent by low-carbohydrate diet before scan - Brain uptake: May obscure local temporal large vessel vasculitis - Bone marrow uptake: Frequently increased nonspecifically due to cytokine activation Important considerations: - Stop glucocorticoids before scan (FDG uptake quickly eradicated by steroids) - Outperforms gallium and leukocyte scintigraphy - May be cost-effective if used early (earlier diagnosis, reduced hospitalization, fewer unnecessary tests) - If performed under right conditions but noncontributory, repeating is of little value unless new signs appear

6.5 Alternative Imaging Modalities¶

When PET/CT unavailable: 67Ga-citrate scintigraphy: - Diagnostic yield: 21-54% - Source correctly localized in approximately one-third of patients 111In- or 99mTc-labeled leukocyte scintigraphy: - Diagnostic yield: 8-31% - Cause correctly identified in approximately one-fifth of patients Full-body MRI: - One study reported diagnostic yield comparable to PET/CT - Further studies needed for confirmation

6.6 Specific Diagnostic Tests¶

Tuberculosis workup: - TST or IGRA: Included in obligatory tests; may be indeterminate in miliary TB, malnutrition, immunosuppression, or anti-IFN γ autoantibodies - Negative TST/IGRA does NOT exclude tuberculosis - If miliary TB suspected: Liver biopsy has highest yield (acid-fast smear, culture, PCR); bone marrow, lymph node, or other organ biopsies also considered - Mycobacterial PCR + culture: May shorten time to diagnosis vs. culture alone Q fever: - Test by immunofluorescence assay (IFA) - Indicated for rural residents, animal product exposure, heart valve disease, aortic aneurysm, vascular prosthesis Whipple's disease: - PCR for T. whipplei on stool and blood - Test early in patients with unexplained CNS, GI, or joint symptoms Temporal artery biopsy: - Recommended for patients ≥ 55 years - Giant cell arteritis often involves large arteries detectable by PET/CT - PET/CT may miss vasculitis limited to temporal arteries (small vessel diameter, high brain FDG uptake) Next-generation sequencing: - May be valuable for rapid detection of infecting microbes - Exact value and application yet to be determined

6.7 Tests with Low Yield Without PDCs¶

The following have very low diagnostic yield in absence of specific PDCs: - Echocardiography - Sinus radiography - Radiologic/endoscopic GI evaluation - Bone marrow biopsy - Liver biopsy - Bronchoscopy CSF examination: - Indicated for FUO with headache - Test for HSV (especially type 2), Cryptococcus neoformans, C. gattii, M. tuberculosis

6.8 Second Opinion at Expert Center¶

Indications: When no explanation found despite complete structured workup Benefits: - Over half of patients with unexplained FUO receive diagnosis at expert center - 1 in 10 remaining undiagnosed patients become fever-free on empirical treatment - Overall beneficial outcome in ~70% of patients referred Rationale: FUO is often atypical presentation of common disease; pattern recognition informed by high exposure is an important diagnostic tool

7. MANAGEMENT & TREATMENT¶

Treatment of FUO is based on the final diagnosis. For patients remaining without a diagnosis, a conservative approach is generally appropriate given the favorable prognosis of most unexplained FUO cases.

7.1 General Principles¶

Rational treatment is based on final diagnosis
The large majority of patients with unexplained FUO spontaneously become symptom-free
Empirical therapeutic trials should be avoided except when patient condition is rapidly deteriorating
Less aggressive diagnostic approach appropriate for clinically stable patients once diseases with immediate therapeutic or prognostic consequences have been excluded

7.2 Pre-Diagnostic Interventions¶

Medications to discontinue during workup: - All antibiotics (sterile cultures unreliable during treatment or within 1 week after) - All glucocorticoids (mask many diseases; lymph node size decreases regardless of cause; eradicates FDG uptake on PET) - All potentially causative drugs for fever evaluation (wait 72h; if fever persists, drug unlikely to be cause)

7.3 Empirical Therapeutic Trials¶

Reserve for rapidly deteriorating patients when diagnosis remains elusive. Commonly used agents: - Antibiotics - Antitubercular agents - Nonsteroidal anti-inflammatory drugs (NSAIDs) - Colchicine - Interleukin-1 inhibitors

7.4 Management of Stable Undiagnosed Patients¶

Follow-up for appearance of new PDCs
Consider NSAID therapy for symptom control
Avoid unnecessary invasive procedures
Reassure regarding generally favorable prognosis

7.5 Case Example: Giant Cell Arteritis Treatment¶

72-year-old woman with 3-month low-grade fever and fatigue; PET/CT showed large-vessel vasculitis and polymyalgia rheumatica: - Treatment: Prednisone 60 mg once daily - Response: Complete recovery within 1 week - Plan: Slow prednisone taper after 1 month

8. PROGNOSIS & COMPLICATIONS¶

The prognosis of FUO depends primarily on the underlying diagnosis. Importantly, most patients with unexplained FUO have favorable outcomes.

8.1 Prognostic Factors¶

Study outcome strongly depends on: - Study design - Origin of cohort - Selection criteria (time-based vs. workup-based) Diagnosis probability: - Higher when older time-based criteria used - Lower when newer criteria with standard basic workup used - 2-5× lower in European vs. Asian patients

8.2 Outcome Without Diagnosis¶

Most patients with unexplained FUO do well
Large majority spontaneously become symptom-free
This supports less aggressive diagnostic approach in stable patients after ruling out diseases with immediate therapeutic/prognostic consequences

8.3 Specific Diagnosis Considerations¶

Common infections (TB, spondylodiscitis, endocarditis) described even in patients with symptom duration >3 months
Lymphoma reported in patients with symptom duration >12 months
Continued vigilance and follow-up required even in long-duration cases

9. SPECIAL CONSIDERATIONS¶

Certain populations and clinical scenarios require modified approaches to FUO evaluation and management.

9.1 Immunocompromised Patients¶

Explicitly excluded from standard FUO definition. These patients require: - Different diagnostic approach - More aggressive workup - Broader differential diagnosis including opportunistic infections

9.2 Elderly Patients¶

Higher prevalence of giant cell arteritis (up to 17%)
Temporal artery biopsy recommended for patients ≥ 55 years
VEXAS syndrome more common in middle-aged to elderly males

9.3 Recurrent Fever Pattern¶

Definition: Repeated episodes of fever/inflammation interspersed with fever-free intervals ≥ 2 weeks with apparent remission Diagnostic implications: - Reduces chance of finding final explanation - Lower prevalence of infections (but not zero) - Diagnostic workup same as continuous inflammation - Advise patients to return during febrile episode - Repeat history, physical examination, laboratory tests during symptomatic phase - Perform further diagnostic tests only during inflammatory episode (abnormalities may be absent between episodes)

9.4 Geographic Considerations¶

Etiology distribution varies by region: Western Europe: - NIIDs most common (~25%) - Infections relatively uncommon (~15%) - High undiagnosed rate (~40%) Asia: - Infections common (~42%) - Tuberculosis accounts for up to 50% of infections Middle East: - Infections predominate (~66%) - Low undiagnosed rate (~8%) Travel considerations: - Tropical countries/American Southwest: Malaria, leishmaniasis, histoplasmosis, coccidioidomycosis - Rural areas: Q fever

9.5 Role of Artificial Intelligence¶

Computer models to predict final diagnosis may: - Shorten diagnostic delay - Guide specific diagnostic testing Limitations: - Only limited data available - Exact value on larger scale, especially across geographic regions, difficult to estimate

10. KEY POINTS & CLINICAL PEARLS¶

Essential clinical pearls for approaching patients with FUO.

10.1 Diagnostic Pearls¶

FUO is usually an atypical presentation of a COMMON disease, not a rare disease
PDCs are the cornerstone of diagnosis—search for them repeatedly through history, examination, and review of tests
Stop all antibiotics and steroids before diagnostic workup
Exclude thermometer manipulation and drug fever early
More than 3 blood cultures or more than 1 urine culture is useless without new PDCs
Negative TST/IGRA does NOT exclude tuberculosis
Granulomatous disease on biopsy should always prompt reconsideration of miliary TB
Cryoglobulin testing is a valuable low-cost screening test
Fundoscopy by ophthalmologist may detect retinal vasculitis early

10.2 Imaging Pearls¶

18F-FDG-PET/CT should be performed during active inflammation (elevated CRP/ESR)
Low-carbohydrate diet before PET prevents cardiac uptake that obscures endocarditis
Stop steroids before PET (FDG uptake eradicated by glucocorticoids)
PET/CT cannot distinguish infection vs. inflammation vs. malignancy—but all cause FUO, so this is an advantage
Normal PET/CT under right conditions: Repeating is of little value unless new signs appear

10.3 Treatment Pearls¶

Most unexplained FUO patients spontaneously improve
Avoid empirical therapeutic trials unless patient is rapidly deteriorating
When empirical therapy needed: Consider antibiotics, anti-TB drugs, NSAIDs, colchicine, or IL-1 inhibitors
After ruling out serious diseases, watchful waiting for new PDCs is appropriate in stable patients

10.4 When to Consider Expert Referral¶

Refer when complete structured workup yields no diagnosis
Expert centers achieve diagnosis in >50% of previously unexplained cases
~10% of remaining undiagnosed patients improve on empirical treatment at expert centers
Overall beneficial outcome in ~70% of referred patients

10.5 Red Flags Requiring Urgent Evaluation¶

Rapidly deteriorating clinical condition
Signs of endocarditis with negative cultures
Suspected miliary tuberculosis
Features suggesting malignancy (lymphadenopathy, unexplained weight loss, night sweats)
Neurological symptoms in setting of FUO (consider CSF examination)